Life Biosciences First Human Readouts
Altos Labs
The key advantage here is not that Life Biosciences is further along on paper, it is that it is already generating the first real human operating data for this category. ER-100 puts an AAV2 vector carrying OCT4, SOX2, and KLF4 directly into the eye in a Phase 1 trial for glaucoma and NAION, which means Life can now measure tolerability, local inflammation, immune reaction, and whether retinal biomarkers move at all in people, while Altos remains at the discovery and platform stage publicly.
-
The eye is the cleanest first test bed for reprogramming. It is a small, contained organ, doctors can inject the therapy locally, monitor vision and retinal structure directly, and limit whole body exposure. That makes Life's dataset unusually valuable for deciding whether OSK can be used safely in humans at all.
-
Because ER-100 is first in humans, Life gets the category's first read on the core translational gap. Mouse and primate restoration data are useful, but they do not answer whether human cells tolerate controlled OSK expression, whether AAV dosing is workable, or whether methylation and tissue readouts shift in patients.
-
This matters competitively because Altos has scale and scientific depth, but no disclosed human candidate yet. Publicly, Altos describes its rejuvenation science platform and leadership buildout, while Life has already crossed the IND and first patient dosing milestones that start defining regulatory precedent for the field.
The next phase is a race to turn reprogramming from an elegant biology story into a repeatable clinical playbook. If Life shows clean safety and even modest biomarker or visual signal, the market will shift toward companies that can pair reprogramming payloads with a practical delivery route and a near term development path, which will increase pressure on Altos to reveal its first clinical program.